---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004194"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:05:01.053760+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ORIC outlines 2023 milestones: initial Phase 1b data expected H2 2023 for three programs

## Summary
- Initial Phase 1b data expected H2 2023 for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2 cancers), ORIC-944 (prostate cancer).
- Pfizer invested $25M in ORIC common stock as part of ORIC-533 clinical collaboration.
- Cash and investments $228M as of Dec 31, 2022; runway into H1 2025.
- Selected PLK4 inhibitor as development candidate for breast cancer (TRIM37-amplified) in Q4 2022.
- All three clinical programs dose-escalating steadily without reaching MTD; global site expansion ongoing.

## SEC filing metadata
- accession: 0001193125-23-004194
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312523004194/0001193125-23-004194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312523004194/d448025d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004194
- JSON: https://secwatch.observer/filing/0001193125-23-004194.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.